Cornercap Investment Counsel Inc. Lowers Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Cornercap Investment Counsel Inc. lowered its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 61.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,027 shares of the biotechnology company's stock after selling 3,257 shares during the period. Cornercap Investment Counsel Inc.'s holdings in United Therapeutics were worth $726,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in UTHR. Meiji Yasuda Asset Management Co Ltd. lifted its holdings in United Therapeutics by 1.6% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company's stock worth $652,000 after purchasing an additional 33 shares during the last quarter. Toronto Dominion Bank lifted its stake in shares of United Therapeutics by 0.8% in the second quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company's stock worth $1,441,000 after buying an additional 37 shares during the last quarter. ClariVest Asset Management LLC boosted its holdings in shares of United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock worth $25,000 after buying an additional 42 shares during the period. Benjamin F. Edwards & Company Inc. grew its stake in United Therapeutics by 14.0% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company's stock valued at $109,000 after buying an additional 42 shares during the last quarter. Finally, First Citizens Bank & Trust Co. raised its holdings in United Therapeutics by 1.8% in the 3rd quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company's stock worth $961,000 after acquiring an additional 48 shares during the period. Institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Down 6.0 %

NASDAQ:UTHR traded down $23.02 during midday trading on Friday, hitting $363.25. The company had a trading volume of 619,978 shares, compared to its average volume of 371,282. The company has a market capitalization of $16.22 billion, a PE ratio of 15.95, a P/E/G ratio of 1.13 and a beta of 0.56. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $417.82. The stock's fifty day moving average price is $362.93 and its 200-day moving average price is $327.52.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts' consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analysts' expectations of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business's revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.38 EPS. As a group, research analysts forecast that United Therapeutics Co. will post 25.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of recent analyst reports. Oppenheimer upped their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, October 31st. Bank of America decreased their target price on United Therapeutics from $303.00 to $280.00 and set an "underperform" rating for the company in a research note on Thursday, August 1st. Argus lifted their price target on United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. HC Wainwright raised their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. Finally, TD Cowen upped their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a research report on Monday, October 21st. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $370.86.

Insider Activity at United Therapeutics

In other news, Director Judy D. Olian sold 1,750 shares of United Therapeutics stock in a transaction on Monday, November 11th. The shares were sold at an average price of $412.48, for a total transaction of $721,840.00. Following the completion of the sale, the director now directly owns 5,655 shares in the company, valued at approximately $2,332,574.40. The trade was a 23.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Michael Benkowitz sold 15,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $401.44, for a total transaction of $6,021,600.00. Following the sale, the chief operating officer now owns 2,577 shares of the company's stock, valued at approximately $1,034,510.88. The trade was a 85.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 113,396 shares of company stock valued at $42,175,418. 11.90% of the stock is owned by corporate insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.